CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer
CRISPR is a customized genome-editing tool that snips DNA in a simpler, cheaper and more precise way than any other gene editing tool. In recent years CRISPR/Cas has completely transformed an existing discipline of genetic engineering. This ‘review’ focuses on the generations and modifications in CA...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222001320 |
| _version_ | 1811295654516883456 |
|---|---|
| author | Afreen Khan Esha Sarkar |
| author_facet | Afreen Khan Esha Sarkar |
| author_sort | Afreen Khan |
| collection | DOAJ |
| description | CRISPR is a customized genome-editing tool that snips DNA in a simpler, cheaper and more precise way than any other gene editing tool. In recent years CRISPR/Cas has completely transformed an existing discipline of genetic engineering. This ‘review’ focuses on the generations and modifications in CAR-T as an advanced cancer therapeutic tool and CAR-T-approved products. It also highlights three path-breaking successful autologous and allogenic ex vivo CAR-T clinical trials in treating cancer using CRISPR/Cas9 which reported successful results despite the controversies regarding the safety of this technique. Outcomes from the first successful clinical trial showed the beneficial long-term effect on genetically modified T-cells in targeting cancer cells which opens the door for CRISPR to be the most preferred technique to help treat cancer and other diseases in the future.We searched the MEDLINE, EMBASE and PUBMED databases for original studies and meta-analysis on the use of CRISPR/Cas9 to edit T-cells until 2021. We finally selected 15 pre-clinical and 26 clinical studies for the review. |
| first_indexed | 2024-04-13T05:36:35Z |
| format | Article |
| id | doaj.art-5d247fdcfdfe447fac11a9a28290dd90 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-04-13T05:36:35Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-5d247fdcfdfe447fac11a9a28290dd902022-12-22T03:00:15ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0133100641CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancerAfreen Khan0Esha Sarkar1Department of Biochemistry, Era's Lucknow Medical College and hospital, Era University, Lucknow, Uttar Pradesh, IndiaCorresponding author.; Department of Biochemistry, Era's Lucknow Medical College and hospital, Era University, Lucknow, Uttar Pradesh, IndiaCRISPR is a customized genome-editing tool that snips DNA in a simpler, cheaper and more precise way than any other gene editing tool. In recent years CRISPR/Cas has completely transformed an existing discipline of genetic engineering. This ‘review’ focuses on the generations and modifications in CAR-T as an advanced cancer therapeutic tool and CAR-T-approved products. It also highlights three path-breaking successful autologous and allogenic ex vivo CAR-T clinical trials in treating cancer using CRISPR/Cas9 which reported successful results despite the controversies regarding the safety of this technique. Outcomes from the first successful clinical trial showed the beneficial long-term effect on genetically modified T-cells in targeting cancer cells which opens the door for CRISPR to be the most preferred technique to help treat cancer and other diseases in the future.We searched the MEDLINE, EMBASE and PUBMED databases for original studies and meta-analysis on the use of CRISPR/Cas9 to edit T-cells until 2021. We finally selected 15 pre-clinical and 26 clinical studies for the review.http://www.sciencedirect.com/science/article/pii/S2468294222001320CAR-TGene editingCRISPR/Cas9Cancer therapiesUniversal CAR-T cells |
| spellingShingle | Afreen Khan Esha Sarkar CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer Cancer Treatment and Research Communications CAR-T Gene editing CRISPR/Cas9 Cancer therapies Universal CAR-T cells |
| title | CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer |
| title_full | CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer |
| title_fullStr | CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer |
| title_full_unstemmed | CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer |
| title_short | CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer |
| title_sort | crispr cas9 encouraged car t cell immunotherapy reporting efficient and safe clinical results towards cancer |
| topic | CAR-T Gene editing CRISPR/Cas9 Cancer therapies Universal CAR-T cells |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222001320 |
| work_keys_str_mv | AT afreenkhan crisprcas9encouragedcartcellimmunotherapyreportingefficientandsafeclinicalresultstowardscancer AT eshasarkar crisprcas9encouragedcartcellimmunotherapyreportingefficientandsafeclinicalresultstowardscancer |